Undas Anetta, Kolarz Marek, Kopeć Grzegorz, Tracz Wiesława
Institute of Cardiology, Jagiellonian University School of Medicine, Cracow, Poland.
Nephrol Dial Transplant. 2008 Jun;23(6):2010-5. doi: 10.1093/ndt/gfm884. Epub 2007 Dec 21.
Haemodialysis patients are at an increased risk of cardiovascular (CV) morbidity and mortality. Both end-stage renal disease (ESRD) and thromboembolic coronary events have been shown to be associated with the formation of dense fibrin clots resistant to fibrinolysis. The aim of the present study was to investigate the effect of long-term haemodialysis on clot structure/function and analyse an influence of markers of inflammation, oxidative stress and lipoprotein(a). We sought also to investigate if clot features might be related to CV events and mortality in haemodialysis patients. Subjects and methods. In 33 patients (19 males, 14 females), aged 27 to 89 years, on long-term haemodialysis and 33 age- and sex-matched apparently healthy controls, we investigated fibrin clot properties and susceptibility to lysis using recombinant tissue plasminogen activator by using permeation and turbidity assays.
Haemodialysis patients produced fibrin clots that had less porous structure (P < 0.0001) were less susceptible to fibrinolysis (P < 0.0001), began fibrin protofibril formation more quickly (P < 0.0001) and showed increased overall fibre thickness (P < 0.0001) compared with controls. Clot permeability and lysis time correlated with F2-isoprostanes (P < 0.01), Lp(a) (P < 0.0001) and fibrinogen (P < 0.01). None of the clot variables showed associations with the duration of haemodialysis treatment or the cause of ESRD. During a 36-month follow-up, 10 CV deaths were recorded. Mortality was associated with reduced clot permeability (P < 0.0001), prolonged lysis time (P < 0.0001), faster fibrin protofibril formation (P = 0.0004), thicker fibres (P < 0.0001) and increased fibrin clot mass (P < 0.0001).
Unfavourably altered clot properties can be detected in haemodialysis patients and may be associated with increased CV mortality.
血液透析患者发生心血管(CV)疾病和死亡的风险增加。终末期肾病(ESRD)和血栓栓塞性冠状动脉事件均已显示与抗纤维蛋白溶解的致密纤维蛋白凝块形成有关。本研究的目的是调查长期血液透析对凝块结构/功能的影响,并分析炎症、氧化应激和脂蛋白(a)标志物的影响。我们还试图研究凝块特征是否可能与血液透析患者的CV事件和死亡率相关。研究对象与方法。在33例年龄27至89岁、接受长期血液透析的患者(19例男性,14例女性)以及33例年龄和性别匹配的明显健康对照者中,我们通过渗透和浊度测定,使用重组组织型纤溶酶原激活剂研究纤维蛋白凝块特性和纤溶敏感性。
与对照组相比,血液透析患者产生的纤维蛋白凝块结构孔隙较少(P < 0.0001),对纤溶的敏感性较低(P < 0.0001),纤维蛋白原纤维形成更快(P < 0.0001),且总纤维厚度增加(P < 0.0001)。凝块渗透性和溶解时间与F2 - 异前列腺素(P < 0.01)、Lp(a)(P < 0.0001)和纤维蛋白原(P < 0.01)相关。没有一个凝块变量与血液透析治疗时间或ESRD病因相关。在36个月的随访期间,记录到10例CV死亡。死亡率与凝块渗透性降低(P < 0.0001)、溶解时间延长(P < 0.0001)、纤维蛋白原纤维形成更快(P = 0.0004)、纤维更厚(P < 0.0001)以及纤维蛋白凝块质量增加(P < 0.0001)相关。
在血液透析患者中可检测到凝块特性发生不利改变,且可能与CV死亡率增加相关。